Key published studies include: Teichman et al., 2006 (JCEM): Dose-dependent GH and IGF-1 elevation with CJC-1295 DAC in healthy adults Raun et al., 1998 (Eur J Endocrinol): Ipamorelin demonstrated selective GH release without cortisol/prolactin elevation Johansen et al., 1999: Phase I/II Ipamorelin trial showed dose-response relationship with no significant adverse effects Bowers et al., 2004: Foundational research on GHRH/GHRP synergistic GH release mechanisms Neither CJC-1295 nor Ipamorelin has completed Phase 3 clinical trials
Patent Filing Patterns by Innovation Category Examining patent activity from 2020 through 2025 reveals clear directional trends across innovation categories, even without precise filing counts
Peptides are short chains of amino acids that act as signaling molecules, telling specific cells to repair tissue, release growth hormone, support metabolism, or rebuild collagen
Decreased expression of miR-126 has been associated with endothelial damage in patients with diabetes and other vascular diseases
What to compare Look at included items, ordering flexibility, and total value before deciding which option to take next